Comparative Pharmacology
Head-to-head clinical analysis: JASCAYD versus NINTEDANIB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JASCAYD versus NINTEDANIB.
JASCAYD vs NINTEDANIB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JASCAYD (tasquinimod) is a selective allosteric inhibitor of S100A9, which binds to toll-like receptor 4 (TLR4) and receptor for advanced glycation end-products (RAGE). It modulates the tumor microenvironment by inhibiting myeloid-derived suppressor cell (MDSC) recruitment and function, reducing angiogenesis, and enhancing anti-tumor immune responses.
Nintedanib is a small molecule tyrosine kinase inhibitor that inhibits multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-α, PDGFR-β), and fibroblast growth factor receptors (FGFR-1, FGFR-2, FGFR-3). It also inhibits RET, FLT3, and Src family kinases. These receptors are involved in angiogenesis, proliferation, and fibrosis.
Adults: 300 mg orally twice daily with food.
150 mg orally twice daily approximately 12 hours apart, taken with food.
None Documented
None Documented
Clinical Note
moderateNintedanib + Digoxin
"Nintedanib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateNintedanib + Digitoxin
"Nintedanib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateNintedanib + Deslanoside
"Nintedanib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateNintedanib + Acetyldigitoxin
"Nintedanib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is 12-15 hours; clinically relevant for once-daily dosing.
Terminal half-life: 9.5 hours (range 6-14 hours) in patients with IPF; supports twice-daily dosing.
Primarily renal excretion (80%) as unchanged drug; 20% fecal via biliary elimination.
Primarily fecal (85%) as unchanged drug; renal excretion accounts for <1%.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor